# US 2025/0375504 A1 · Semaglutide for use in medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375504 A1
- Document ID: US20250375504A1
- Status: Published application
- Kind: A1
- Application number: 19/310,993
- Filed: 2025-08-27
- Published: 2025-12-11
- Earliest claimed: 2020-04-27
- Assignees: Novo Nordisk A/S
- Applicants: Novo Nordisk A/S
- Inventors: Morten Hansen; Martin Linder; Carl Richard Torstenson; Mads Sundby Palle; Lars Holm Damgaard
- Web page: https://patentgrep.com/patent/US20250375504A1

## CPC

- A61K 38/26: Glucagons
- A61K 47/02: Inorganic compounds
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.

## Claims

### Claim 1

A method of treating non-alcoholic steatohepatitis (NASH), comprising administering semaglutide subcutaneously in an amount of about 1.7 mg per week to a subject diagnosed with NASH, wherein the administering results in an improvement in lobular inflammation.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the subject does not have cirrhosis.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the semaglutide is administered once daily or less frequent.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the semaglutide is administered once weekly.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the method provides no worsening of liver fibrosis in the subject.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the semaglutide is administered to the subject in an amount of 1.7 mg per week.

### Claim 7

A method of treating non-alcoholic steatohepatitis (NASH), comprising administering semaglutide subcutaneously in an amount of about 1.7 mg per week to a subject diagnosed with NASH, wherein the administering results in resolution of NASH and no worsening of liver fibrosis.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the subject has liver fibrosis stage 2.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the subject has liver fibrosis stage 3.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the semaglutide is administered once weekly.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the subject has liver fibrosis stage 2.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the subject has liver fibrosis stage 3.

### Claim 13 (depends on 7)

The method according to claim 7, wherein the semaglutide is administered in an amount of 1.7 mg.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the subject has liver fibrosis stage 2.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the subject has liver fibrosis stage 3.

### Claim 16 (depends on 7)

The method according to claim 7, wherein the semaglutide is administered in an amount of 1.7 mg once weekly.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the subject has liver fibrosis stage 2.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the subject has liver fibrosis stage 3.

### Claim 19

A method of treating non-alcoholic steatohepatitis (NASH), comprising administering semaglutide subcutaneously in an amount of about 2.4 mg per week to a subject diagnosed with NASH, wherein the administering results in resolution of NASH and no worsening of liver fibrosis.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the subject has liver fibrosis stage 2.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the subject has liver fibrosis stage 3.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the semaglutide is administered once weekly.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the subject has liver fibrosis stage 2.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the subject has liver fibrosis stage 3.

### Claim 25 (depends on 19)

The method according to claim 19, wherein the semaglutide is administered in an amount of 2.4 mg.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the subject has liver fibrosis stage 2.

### Claim 27 (depends on 25)

The method according to claim 25, wherein the subject has liver fibrosis stage 3.

### Claim 28 (depends on 19)

The method according to claim 19, wherein the semaglutide is administered in an amount of 2.4 mg once weekly.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the subject has liver fibrosis stage 2.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the subject has liver fibrosis stage 3.
